Chamberlain College of Nursing, a subsidiary of DeVry Education Group Inc. DV, recently opened a new campus in Pearland, TX. The 14th Chamberlain campus in the U.S., the Pearland campus, has already begun the admission process for the fall semester, which begins in Sep 2014.
The new Pearland campus offers an on-site Bachelor of Science in Nursing, a 3-year program instead of the regular 4-year programs. The campus also incorporates a Simcare Center with high-tech simulated patient care facilities in a clinical learning environment. The campus will also incorporate a Center for Academic Success aimed to provide academic resources and support for to students. Students will also benefit from the student centric learning environment, small class size, diversified clinical learning facilities and experimental learning.
The Pearland campus is only 25 miles from Chamberlain's Houston campus and is also close to the Medical Center. Being Chamberlain's second campus in Texas, Pearland will cater to the increasing demand for nurses in the state. Demand for nursing programs is expected to increase further as more and more students opt for this lucrative career option.
Chamberlain is one of the growing institutions of DeVry. Moreover, DeVry's medical schools produce strong student outcomes and have very low cohort default rates. DeVry draws a significant portion of its revenue from healthcare programs. The latest campus addition will contribute to its revenues going forward.
DeVry Education carries a Zacks Rank #2 (Buy).
Key Picks from the Sector
Some other stocks in the education sector worth considering include Lincoln Educational Services Corp. LINC, Strayer Education Inc. STRA and Apollo Education Group, Inc. APOL. While Lincoln Educational Services sports a Zacks Rank #1, Strayer Education and Apollo Education carry a Zacks Rank #2.
DEVRY EDUCATION DV: Free Stock Analysis Report
STRAYER EDUC STRA: Free Stock Analysis Report
APOLLO GROUP APOL: Free Stock Analysis Report
LINCOLN EDUCATL LINC: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.